Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial - Hugues Chabriat, Claudio L. Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M. Hermann, Katharina Althaus, Sergi Amaro, Hee-Joon Bae, Zbigniew Bak, Leonardo Barbarini, Pietro Bassi, Rodrigo Bazan - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, The Lancet Neurology, 3(19), p. 226-233, 2020

DOI: 10.1016/s1474-4422(20)30004-1

Links

Tools

Export citation

Search in Google Scholar

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial

Journal article published in 2020 by Hugues Chabriat, Claudio L. Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M. Hermann, Katharina Althaus, Sergi Amaro, Hee-Joon Bae, Zbigniew Bak, Leonardo Barbarini, Pietro Bassi, Rodrigo Bazan and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO